Second primary malignancies after CAR T-cell therapy: causal attribution, clonal evolution, and risk-adapted surveillance
Background Chimeric antigen receptor (CAR) T-cell therapy can produce durable remission in refractory hematologic malignancies, but the expanding survivor population has focused attention on second primary malignancies (SPMs). Interpretation is difficult because recipients already carry substantial age-, disease-, and treatment-related cancer risk; follow-up is often short; outcome definitions vary; and competing mortality is high. Main body This critical review integrates epidemiologic, genomic, mechanistic, and regulatory evidence into a causal framework. Available evidence is consistent with a multistep clonal-evolution model: pre-existing clonal hematopoiesis and cumulative genotoxic injury establish the substrate; lymphodepletion, marrow inflammation, regenerative stress, and altered immune surveillance modify clonal fitness; and additional events permit transformation. Therapy-related myeloid neoplasms are the most actionable subgroup. By contrast, T-cell malignancies derived from CAR-modified cells are exceptionally rare and require direct lineage and vector analysis because detection of a CAR sequence alone does not prove insertional oncogenesis. We propose a graded attribution ladder and a risk-adapted surveillance pathway centered on serial blood counts, prompt evaluation of unexplained cytopenias or lymphoid abnormalities, age-appropriate cancer screening, and mechanism-specific molecular testing. Conclusion Temporal association should not be equated with causation. Prospective denominator-based cohorts, matched comparators, paired biospecimens, integration-site mapping, and single-cell lineage reconstruction are needed to distinguish background risk, treatment-associated clonal selection, and true product-related oncogenesis.
Authors
- 吴功强
- Panruo Jiang (ORCID: https://orcid.org/0009-0000-3118-8278)
- Sihui Huang
- Yang Jin
Institutions
- Wenzhou Medical University (CN)
- Dongyang People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fimmu.2026.2014066
- Primary Topic
- Multiple and Secondary Primary Cancers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jinhua Science and Technology Bureau
- Science and Technology Program of Zhejiang Province